At the moment, there are no entries available for display
From the Leadership
Group Finance Review
The 2023-24 financial year was a period that saw improved performance across Sunshine Holdings PLC’s three verticals Healthcare, Consumer Goods and Agribusiness, with significant increases in revenue and profitability for many of our nine business units.
66%
Year-on-year profit growth
As the operating environment gradually stabilised during the reporting period under a long overdue macroeconomic reform programme, the sectors Sunshine does business in made significant recovery, resulting in the Group making much headway in its growth agenda.
The macroeconomic climate during the year under review was influenced by three fundamentals: interest rate, exchange rate, and inflation, each of which this review will examine in detail.
An easing interest rate
To curb galloping inflation that was eroding real incomes and tailspinning the economy at the height of the 2022 financial crisis, the Central Bank tightened its monetary policy by record levels, with interest rates peaking at 28%. However, as the impact of stabilisation efforts began to take root, the authorities eased the policy rates, averaging at 14% during the year, providing businesses including our own with much needed breathing room in the wake of the crisis.
The availability of credit allowed for greater support for working capital. Sunshine’s working capital leverage, capped at a rule-of-thumb maximum of 40% at the Group level, reached 36-39% during the crisis but has since decreased to 29% due to conservative borrowing practices. Approximately 75-80% of our borrowing is for short-term working capital, with the remainder for long-term purposes, including a loan for the acquisition of Daintee funded through the International Finance Corporation (IFC), which is hedged at a fixed rate of 12.5% for seven years.
At the outset of the new fiscal year, the interest rate stands at around 10%, which is sufficiently favourable for businesses in the current climate. We expect rates to remain between 11-12% for the rest of the 2024-25 period, allowing for more credit growth in the market and higher utilisation of working capital borrowings from our end.
A stable exchange rate
Several of our business activities are import-dependent and, as a result, are highly sensitive to exchange rate fluctuations. The US dollar peaked at Rs. 395 during the previous financial year but had since stabilised around Rs. 330 and subsequently dropped to somewhere around Rs. 295-300. The appreciation of the rupee has proved notably beneficial to our healthcare segment and also other businesses that rely on the import of raw materials. It did have a negative impact on our tea export business.
We appreciate the Central Bank’s efforts over the last 12 months to maintain currency stability, especially in view of increased Forex inflows from tourism and worker remittances, and we are hopeful that this will continue into the new financial year.
Inflation
Sri Lanka saw unprecedented levels of inflation during the 2022-23 financial year, with the rate of price increases reaching as high as 70% at the peak of the crisis. Thanks to a number of factors, not the least of which were the International Monetary Fund (IMF)-backed reforms, inflation came down to single digits under a year later, a remarkable achievement to say the least. Despite a slight uptick to around 2 to 3% in December 2023, headline inflation by March 2024 had dropped to 0.9%.
Financial Performance
During the reporting period, Sunshine Holdings PLC (SUN) recorded a consolidated revenue of Rs. 55.5 Bn. for the year ended 31 March 2024, representing a 7.0% year-on-year growth. The revenue was driven by Healthcare (50%), Consumer brands (35%), and Agribusiness (15%).
Gross profit margin improved by 500 basis points to 31.0%, resulting in a gross profit increase of Rs. 3.7 Bn. (27.6% YoY). Operating profit (EBIT) grew by 23.7% to Rs. 8.7 Bn., despite higher operating expenses. Profit after tax (PAT) rose significantly to Rs. 6.0 Bn. from Rs. 3.6 Bn. the previous year, aided by the improvement of gross profit margin, finance costs decreased to Rs. 1.2 Bn., down from Rs. 1.5 Bn. last year, supported by favourable interest rates. Profit attributable to equity shareholders (PATMI) nearly doubled, reaching Rs. 4.5 Bn.
We wish to note that, going into the new financial year, Sunshine maintains a strong financial position with a satisfactory debt-to-equity ratio, keeping borrowing primarily for short-term working capital. Our credit rating also remained stable at AA+lka (Outlook Stable), as affirmed by Fitch Ratings, during the review period.
Dividends
Our dividend policy remained unchanged during the year under review. The Group has access to the necessary funds to finance and interim dividends of Rs. 1.00 and the proposed final dividend of Rs. 2.00 per share, totalling to Rs. 3.00, and the Company’s independent auditors will certify the requisite solvency levels for the payment of the proposed dividend.
Revenue grew by 16.1% YoY, driven by the Medical Devices Division and Pharma manufacturing. The EBIT margin improvement was due to higher contributions from these segments and favorable price adjustments. The pharmaceutical segment remained stable, and the medical devices segment saw a 28.1% YoY increase. Healthguard Pharmacy experienced a 19.2% YoY increase in revenue. Lina’s revenue grew by 137.4% YoY due to higher capacity utilisation.
Revenue reached Rs. 19.3 Bn., a 1.6% YoY increase. The domestic consumer brands performed well despite challenges, with tea segment revenue growing by 19.0% YoY. The export business faced a 22.5% YoY revenue decline due to currency appreciation and lower tea prices. The EBIT margin improved to 27.5%, driven by the domestic tea segment. PAT from the Consumer sector grew by 119% YoY.
Revenue declined by 5.1% YoY to Rs. 8.3 Bn., primarily due to a 9.3% decline in palm oil revenue despite a 15.2% increase in production. The dairy business grew by 29.7% YoY, reducing its net loss to Rs. 139.2 Mn. from Rs. 320.9 Mn. PAT for the Agribusiness sector remained constant YoY.
Future
Outlook
Going into the new fiscal year, each business segment has already formulated tailored strategies to sustain and grow their operations with this in mind.
SUN announced a proposed equity investment of up to Rs. 3,270 Mn. by the International Finance Corporation (IFC) into Sunshine Healthcare Lanka (SHL), giving IFC approximately 14.7% stake in SHL, subject to satisfying conditions precedent. This investment is expected to enhance SHL’s operations significantly.
The Group is optimistic about navigating macroeconomic challenges while maintaining a consumer-centric approach. The Healthcare sector will focus on growth opportunities, and the Consumer sector will address macroeconomic pressures. The Agribusiness sector anticipates stable palm oil prices and improved crop volumes, along with steady milk yields and reduced feed costs.
Aruna Deepthikumara
Group Chief Financial Officer
30 May 2024